Resuli Blerina, Kauffmann-Guerrero Diego, Behr Jürgen, Tufman Amanda
Department of Medicine V, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.
Comprehensive Pneumology Center Munich, German Center for Lung Research, Munich, Germany.
JTO Clin Res Rep. 2024 Sep 7;5(12):100719. doi: 10.1016/j.jtocrr.2024.100719. eCollection 2024 Dec.
mutation and amplification have been identified as distinct molecular targets in lung cancer with different therapeutic and prognostic values. The coexistence of and mutations is extremely rare, and therefore, no data exist on the best treatment in these cases.
突变和扩增已被确定为肺癌中具有不同治疗和预后价值的独特分子靶点。两种突变同时存在极为罕见,因此,尚无关于这些病例最佳治疗方法的数据。